- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
Search Results
240 results for dgse
Moderna Stock Looks Like a Winner as the Covid-19 Vaccine Race Loosens
Moderna looks like it has a winner with its Covid-19 vaccine. MRNA stock could make $35 billion if it delivers 1 billion doses, making its…
Why Moderna Has More Upside Than Its Covid-19 Vaccine Implies
The wild volatility in Moderna stock before and after its vaccine approval is coming to an end but its long-term prospects are on the way…
Marijuana News: Teva Pharmaceuticals Industries Ltd (ADR) Signs Cannabis Inhaler Deal
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) has some good marijuana news for those living in Israel that want to inhale the drug.
Moderna Has Huge Growth Potential As Its Covid-19 Trials Wrap Up
Phase 3 trials for Moderna’s coronavirus vaccine candidate could mean $37 billion in revenue for MRNA stock if mRNA-1273 wins approval.
Novavax Is a Vaccine Investment That You Shouldn’t Ignore
It makes sense to hold your NVAX stock shares now as Novavax is working hard to promote the distribution of its Covid-19 vaccine doses.
With the European Union Buying Doses, Novavax Has Plenty of Upside Left
Novavax secured a supply agreement with the European Union, which is a sign of confidence for its vaccine. NVAX stock could move higher from here.
UnitedHealth Group Inc Stock Requires Big Dose of Caution
UNH stock has been on a tear but there are long term issues with the company.
Lowe’s Companies, Inc.: Get a Dose of Relative Strength With LOW Stock
Lowe’s (LOW) stock tenaciously held support even during the broader market weakness in late August. Now, investors can ride a build in relative strength.
Bristol-Myers Squibb Co (BMY) Suffers Heavy Dose of Disappointment
BMY stock — at around $49 — is now fairly valued. But given its failure rate, waiting for Bristol-Myers to get to “cheap” is the…
FDA Pulls Approval for a Generic Antidepressant
A generic version of antidepressant Wellbutrin has lost FDA approval after tests showed it less effective than the brand name drug at a certain dosage.
Novavax Stock Is a Buy Even After the Company’s Post-Dip Bounce
NVAX stock seems attractive for accumulation in the recent correction. Vaccine focus on low-income countries is likely to deliver growth.
Moderna Stock Is Worth Much More
Moderna reaps the rewards of its Covid-19 vaccine, and MRNA stock is worth 57% to 172% more based on near-term and long-term earnings power.
CureVac Is a Bet on a Safe and Effective Vaccine
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over…
Pfizer May Have Found a New Hit Drug
The drug company’s new medication could be a game-changer. See what it treats and why one analyst thinks it’s a home run.
Revelation Biosciences (REVB) Stock Soars 120%
REVB stock is soaring 120%, but no news explains the rally. The firm recently finished dosing patients for a trial of its hay fever drug.
Alphabet Should Be on Every Technology Investor’s Radar Now
Skeptics might claim the Google search engine is “dead,” but a dose of common sense should get investors to lean bullish on GOOG stock.
Meet Your New Robot Overlords – Morning Linkfest (June 6)
InvestorPlace’s daily dose of some of the best reads elsewhere on Wall Street. Today’s top stories: robots, goats and junk bonds.
Ocugen Just Overcame a Serious Hurdle
OCGN stock has skyrocketed on positive Phase 3 results. But the company is facing tough competition.
The Vaccine Race Is Far From Over, And That’s Good News for Novavax
Bill Gates expects Novavax’s vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today?
Dyne Therapeutics stock is rising higher on Wednesday as investors in DYN react to positive clinical trial news from the company.
Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data
Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial.
Covid-19 Vaccine Orders Are Piling Up, Moderna Stock Has Room to Grow
With production ramping to 1.4 billion doses and next-gen vaccine in trials, don’t underestimate Covid-19 vaccine upside for MRNA stock.
5 – 10 of 240 results
